TMCI Earnings Prediction
The chart below shows how TMCI performed 10 days before and after its earnings report, based on data from the past quarters. Typically, TMCI sees a +4.31% change in stock price 10 days leading up to the earnings, and a -5.08% change 10 days following the report. On the earnings day itself, the stock moves by -1.35%. This data can give you a slight idea of what to expect for the next quarter's release.
TMCI Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
68.71M
10.44%
52.39%
Gross Margin
80.74%
-1.01%
0.75%
Operating Margin
-0.30%
-97.25%
-99.11%
Net Margin
-0.73%
-92.77%
-97.86%
EPS
-0.01
-90.00%
-96.00%
No Data Available
TMCI Earnings Analysis
Treace Medical Concepts Inc Corporation (TMCI.O) Earnings Conference Call
Positive
Q4 2024 Revenue Surge: Revenue growth of 10.4% in Q4 2024, reaching $68.7 million, driven by increased adoption of new technologies and a growing base of surgeon customers.
Revenue Increase Projection: Full-year 2024 revenue of $209.4 million, a 12% increase over 2023, at the top-end of guidance expectations.
Innovative Product Launches: Introduction of innovative products like Adductoplasty and SpeedPlate, which are gaining traction among surgeons and contributing to revenue growth.
New Technology Launch Impact: Successful launch of new technologies such as Nanoplasty and Percuplasty, expected to ramp up availability and revenue impact in 2025.
Adjusted EBITDA Surge: Improvement in adjusted EBITDA for Q4 2024, reaching $11.1 million, a 322% increase compared to Q4 2023.
Strong Cash Position: Strong cash position with $75.7 million in cash and equivalents, plus access to an additional $26 million, providing flexibility for strategic investments.
2025 Revenue Guidance Initiation: Initiation of full-year 2025 revenue guidance of $224 million to $230 million, indicating expected growth of 7% to 10% over 2024 revenue.
Negative
Q4 2024 Revenue Performance: Revenue growth of 10.4% in Q4 2024 was at the top-end of expectations, but still reflects a modest increase compared to previous years.
Gross Margin Decline: Gross margin decreased from 81.6% in Q4 2023 to 80.7% in Q4 2024, indicating a decline in profitability.
Operating Expenses Increase: Operating expenses increased for the full-year 2024, rising to $224 million from $203.4 million in 2023, driven by higher stock-based compensation and investments in product innovation.
Increasing Net Loss: Net loss for the full-year 2024 was $55.7 million, which is an increase from a net loss of $49.5 million in 2023, indicating worsening financial performance year-over-year.
Adjusted EBITDA Performance: Despite a significant improvement in adjusted EBITDA for Q4 2024, the full-year adjusted EBITDA loss was still substantial at $11 million, reflecting ongoing financial challenges.
Modest Revenue Expectations: The company expects only a 7% to 10% revenue increase for 2025, which may not be sufficient to offset previous losses or to indicate strong growth potential.
TMCI FAQs
How does TMCI typically perform around its earnings report dates?
Is Treace Medical Concepts Inc (TMCI) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
TMCI Earning Call Sentiment
Treace Medical Concepts, Inc. (NASDAQ:TMCI) Q4 2024 Earnings Call Transcript
TMCI.O
-1.72%Positive
The earnings call reveals strong financial performance with 10% revenue growth in Q4 and a 12% increase for 2024, despite a slight decline in gross margins. Guidance for 2025 shows continued revenue and EBITDA improvement. Product innovation and market expansion efforts are promising, though competitive pressures and supply chain challenges exist. The Q&A indicates positive sentiment from analysts, with expectations for higher growth in later quarters. No share repurchase plan is a minor negative, but overall, the combination of positive financials, optimistic guidance, and product pipeline supports a positive stock price reaction.
